The efficiency of clinical trial designs for predictive biomarker validation
Lists
Only you see this
Abstract
The marker-based strategy designs are less efficient than the traditional design in general. If there is no treatment effect among marker-negative patients, it is still feasible to use the marker-based strategy design I if the assay sensitivity is high. If the treatment effect among marker-negative patients is half of the effect among marker-positive patients, the marker prevalence must be relatively high and the sensitivity of the assay must be very high for the marker-based strategy design I to approximate the efficiency of the traditional design. The efficiency of the marker-based strategy design II relative to the traditional design is low in all scenarios considered under the current study.
BibTeX
@inproceedings{young2010efficiency,
author = {KY Young and Amy Laird and Xiao‐Hua Zhou},
title = {{The efficiency of clinical trial designs for predictive biomarker validation}},
booktitle = {Clinical},
year = {2010},
doi = {10.1177/1740774510370497},
}Loading related content...